Abstract Neurodegenerative diseases are characterized by the progressive loss of specific neurons in selected regions of the central nervous system. The main clinical manifestation (movement disorders, cognitive impairment, and/or psychiatric disturbances) depends on the neuron population being primarily affected. Parkinson's disease is a common movement disorder, whose etiology remains mostly unknown.
Introduction
Neurodegenerative disorders are characterized by the progressive deterioration of neuronal systems in the central nervous system (CNS). The loss of neurons results in movement disorders, cognitive impairment, and/or psychiatric disturbances. The pathological defects that underlie neurodegenerative disorders are fairly well defined and usually involve the progressive death of specific neurons in selected regions of the CNS. Despite their distinct etiologies, neurodegenerative disorders probably share pathogenetic mechanisms that involve oxidative stress, unfolded protein response, and mitochondrial impairment [1] . Although the main clinical manifestations of each disorder depend on the neuron population being primarily affected, some individuals show signs and symptoms indicating the extension of the pathology to other systems [2] [3] [4] .
Parkinson's disease (PD) is a multi-factorial neurodegenerative disorder, whose etiology remains largely unknown. Early in the course of the disease, the symptoms are movement-related, including tremor, rigidity, slowness of movement, and difficulty with walking and gait [5, 6] . Progressive impairment of motor control is caused by the specific loss of dopaminergic neurons in the substantia nigra (SN) and the formation of intraneuronal proteinaceous inclusions, called Lewy bodies (LBs) [7, 8] . The progressive deterioration of vulnerable SN dopaminergic neurons may arise from cellular disturbances caused by misfolding and aggregation of the synaptic protein alpha synuclein [9] , the disruption of the autophagy-lysosome system [10] , mitochondrial dysfunction [11] , endoplasmic reticulum (ER) stress [12] , and dysregulation of calcium homeostasis [13] . These pathways are not specific for PD but they are shared by Alzheimer's disease (AD) [14] and amyotrophic lateral sclerosis (ALS) [2] , and there is recent evidence supporting the view that ALS and PD share common pathogenetic mechanisms. Indeed, the frequency of extra-pyramidal symptoms in ALS patients is significantly higher than in the general population [15, 16] .
Current research on the molecular bases of neurodegenerative disorders using omic technologies (e.g., genomics, proteomics, and metabolomics) have enabled high-throughput monitoring of a variety of molecular and organismal processes. These techniques have been generally applied to identify biological variants, to characterize the involved complex biochemical systems and to study pathophysiological processes. While many omics platforms target comprehensive analysis of genes (genomics), mRNA (transcriptomics), proteins (proteomics), and metabolites (metabolomics) [17] , challenges remain for omics-domain data integration [18] . Changes in mRNA levels do not always correlate with similar changes in protein levels or activity; therefore, studies evaluating protein expression changes in neurodegenerative models are crucial [19] . The most common methods of proteome analysis are the comparative two-dimensional electrophoresis (2-DE), followed by mass spectrometry (MS), and shotgun proteomics, based on a gel-free approach. 2-DE shows a better workbench for the characterization of post-translational modifications. However, shotgun proteomics provides a better sensitivity and resolution [20] .
In the present study, we analyzed the biological processes that result to be altered in PD, making a comparison with two other neurodegenerative disorders: AD, as the most studied neurodegenerative condition, and ALS, as a movement disorder affecting the motor neurons, instead of a midbrain neuron population as in PD. To this end, we performed a meta-analysis of the literature encompassing all the proteomic investigations published so far concerning neuronal alterations in PD, ALS, and AD. Unlike the meta-analysis of clinical studies, we collected all data on proteins that have been reported to be quantitatively altered in either diseases. We then combined these data with disease-linked genes taken from curated diseasegene databases (DisGeNET) [21] in order to unveil diseasespecific biological pathways. This allowed us to obtain an enriched dataset for the following system biology analysis [19] .
Materials and Methods

Input List Generation
A meta-analysis of the literature was obtained by gathering all proteomic investigations of neuronal alterations in PD, ALS, and AD. The search was conducted in PubMed database, using the following search terms: Bproteom*[Title/Abstract]) AND Parkinson* [Title/Abstract]^. All English language studies found in the database and published within the end of 2015 were considered. Only full-text original articles focused on the development of the disease in the CNS were included. Therefore, all papers on peripheral biomarkers and on the drug influence on the pathogenesis were manually filtered out. All protein IDs reported to be altered by the disease were retrieved manually both in the main text and in the supplementary materials and were converted to the corresponding human Uniprot ID. Genetic information taken from the curated database DisGeNET (http://disgenet.org, v4 released April 15th 2016) were also collected. The following search terms were used in DisGeNET: PD (umls:C0030567), ALS (umls:C0002736), and AD (umls:C0002395).
Bioinformatic Analysis
By merging the protein input lists for the three diseases, proteins were divided between disease-specific (only-PD_Proteins, onlyALS_Proteins, and only-AD_proteins) and in common among different disease states. In order to identify genes and proteins specific for PD (PD_Proteins-Genes), the tool InteractiVenn was used (http://www.interactivenn.net/) [22] .
The over-representation analysis (ORA) was carried out using the GO Consortium (http://geneontology.org/ ) and Reactome (http://www.reactome.org/) databases. Only significant pathways (p value <0.05) were taken into account. In order to compare the results obtained after the analysis of the input lists, we used GOView (http://www. webgestalt.org/GOView/). GOView is a web-based application which allows both visualization and comparison of multiple GO term lists in a directed acyclic graph (DAG) able to unveil relationships among terms.
Networks were built using the web portal BioProfiling (http://www.bioprofiling.de). This tool includes almost all the available information concerning signaling and metabolic pathways (databases: Reactome and KEGG) and physical protein-protein interaction (PPI) (database: IntAct) [23] . Accordingly, the protein input list was analyzed with the PPI spider [24] tool. The p value provided, computed by Monte Carlo simulation, refers to the probability to get a model of the same quality starting from a random gene list of the same size [23] . The significant D1 networks (all nodes belong to the input list, p < 0.01) were considered to further interpret and discuss proteomic results. The networks were exported as .xgmml files and edited using Cytoscape 3.2.0 (http://www. cytoscape.org/) [25] .
To perform network topology analysis of the enriched networks, we used the NetworkAnalyzer Cytoscape application. NetworkAnalyzer performs analysis of biological networks providing network topology parameters including the diameter of a network, the average number of neighbors, and the number of connected pairs of nodes. Distributions of more complex network parameters such as node degrees, average clustering coefficients, topological coefficients, and shortest path lengths were also computed [26] . Again, the GO Consortium was used to perform ORA (GO terms).
Western Blot Analysis of SN Samples
Mesencephalic tissues from five sporadic PD patients and five controls (defined by the Brain Bank as non-demented, since they did not show any sign of dementia at the time of death) (Supplementary Table 1) were obtained from the Netherlands Brain Bank (NBB), Netherlands Institute for Neuroscience, Amsterdam. All material has been collected from donors for or from whom a written informed consent for brain autopsy and the use of the material and clinical information for research purposes had been obtained by the NBB.
The tissue specimens (approximately 12 mg) were put in a Potter homogenizer together with 500 μl of tissue lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton, 2 mM ethylenediaminetetraacetic acid (EDTA) 1 mM 1,4-dithiothreitol (DTT), 1× phosphatase inhibitors (Roche), 1× phenylmethylsulfonyl fluoride (PMSF), 1× protease inhibitor cocktails (PICs)), and then manually lysed. After this procedure, the samples were incubated on ice for 30 min and then sonicated (0.5 cycles, 15 pulses, twice). Then, the lysates were centrifuged at 18,000×g for 15 min at 4°C.
Total protein concentration was quantified using the bicinchoninic acid (BCA) method (Pierce). Equal amounts of proteins were resolved in 10% sodium dodecyl sulfate (SDS,TGX Stain-Free FastCast Acrylamide Kit, 10%, BioRad) and the fluorescent stain activated by UV light, following manufacturer's instructions. Then, proteins were transferred to polyvinylidene difluoride (PVDF) membranes at 1.0 mA/cm 2 for 2 h (TE77pwr; Hoefer) and the fluorescent signal acquired (GelDoc-Ite Imaging System; UVP). Membranes were saturated for 2 h at room temperature in Tris-buffered saline Tween (TBST), integrated with 5% of skimmed milk powder, and then incubated with anti-TALDO1 (Abcam ab67467,1:500) and β-actin (GeneTex GTX23280, 1:8000) primary antibody overnight at 4°C, in 5% milk-TBST. Incubation with anti-mouse (Millipore 12-349, 1:1500) peroxidase-conjugated secondary antibody in 5% milk-TBST was then performed. Enhanced chemiluminescence substrate (Millipore Corporation) was used in order to visualize the peroxidase signals: images (16 bit grayscale) were finally acquired using the G:BOXChemi XT4 (Syngene) system and analyzed using the ImageJ software [27] (https://imagej.nih.gov/ij/), normalizing each TALDO1 signal for the β-actin signal.
Results
Assembly of Gene and Protein Lists
In order to gather valuable information for the assembly of the input lists, a meta-analysis of the literature was performed, including all the proteomic investigations of AD, PD, and ALS disease models. Full texts of the selected articles were used to extract information about proteins altered by the three diseases and to generate the input lists (Table 1) . We identified 762, 420, and 139 papers in PubMed about proteomic investigations in AD, PD, and ALS, respectively. The studies retained (healthy/disease comparison and quantitative proteomic studies) were 40 for AD, 46 for PD and only 9 for ALS (Supplementary Table 2 ). We generated three input lists: AD_Proteins (928 proteins), PD_Proteins (1155 proteins), and ALS_Proteins (387 proteins) ( Table 1) .
We analyzed the three lists in order to identify proteins that were not unique to a specific disease (Fig. 1) . On the other hand, we observed that 675 proteins resulted to be altered in PD only (only-PD_Proteins input list). As far as the intersections are concerned, PD and ALS shared 69 proteins, while AD and ALS showed only 29 proteins in common.
We then included genetic information extracted from the curated database DisGeNET, and we obtained three additional input lists called AD_Genes, PD_Genes, and ALS_Genes, respectively (Table 1) .
In order to identify both proteins and genes exclusively associated with PD, we used the InteractiVenn tool (Fig. 2) . As a result, we identified 25 IDs that were present in both PD_Proteins input list and PD_Genes input list and not present in any other protein or gene list. The 25 IDs were aromatic-L-amino-acid decarboxylase (DDC), GTP cyclohydrolase 1 (GCH1), disk large homolog 2 (DLG2), fructose-1,6-bisphosphatase 1 (FBP1), 60S ribosomal protein L6 (RPL6), 60S ribosomal protein L23a (RPL23A), 40S ribosomal protein S8 (RPS8), 60S ribosomal protein L14 (RPL14), transaldolase 1 (TALDO1), ribosyldihydronicotinamide dehydrogenase [quinone] (NQO2), glutamate decarboxylase 1 (GAD1), OX-2 membrane glycoprotein (CD200), Wolframin (WFS1), pyridoxal kinase (PDXK), AP-1 complex subunit mu-1 (AP1M1), beta-2-microglobulin (B2M), nucleotide-binding oligomerization domain-containing protein 2 (NOD2), sideroflexin-2 (SFXN2), fibrillin-1 (FBN1), glutamate dehydrogenase 2, mitochondrial (GLUD2), Heat shock 70 kDa protein 1-like (HSPA1L), retinal dehydrogenase 1 (ALDH1A1), mesencephalic astrocyte-derived neurotrophic factor (MANF), small nuclear ribonucleoprotein F (SNRPF), and ubiquitin-conjugating enzyme E2 S (UBE2S) (PD_Proteins-Genes input list) (Supplementary Table 3 ).
Verification of Transaldolase 1 as a PD Protein
As a proof of principle, we selected one protein in the list of the 25 PD unique IDs to verify its up-regulation in PDaffected tissues, as suggested by the bioinformatic analysis. We checked TALDO1 abundance in SN samples obtained from five sporadic PD patients and five matched control subjects. As shown in Fig. 3 , we verified TALDO1 increase in the affected tissue of sporadic PD patients.
Over-Representation of Biochemical Pathways and Gene Ontology Categories
In order to understand which cellular pathways are mainly affected by the three disease conditions examined, an ORA was performed on the six input lists (the three B_Proteinsî nput lists and the three B_Genes^input lists), using the gene ontology (GO) enrichment tool of the GO consortium. Given the huge amount of results obtained, we used GOView to select and sum up the most relevant information (Tables 2  and 3 ).
The Bapoptotic process^served as an internal control, since alterations in the apoptotic pathway resulted to be present in all of the three diseases (PD, AD, and ALS). Similarly, the ORA analysis unveiled the alteration of protein transport as a common feature of the three diseases (Bprotein targeting^and Bregulation of protein transport^). On the other hand, the ORA allowed us to identify disease-specific pathways. Indeed, in PD, we recognized a central role for mitochondria both in B_Proteins^(Bmitophagy^and Bmitochondria localization^) and in B_Genes^analyses (Bapoptotic mitochondria change^). Furthermore, alterations in proteasomal function (Bproteolysis involved in cellular protein catabolic process^) and Bresponse to oxygen radical^were observed. By contrast, cytoskeleton organization, ion homeostasis and lipid biosynthetic process resulted to be altered in AD, while aberrant RNA processing appeared to be mainly involved in ALS pathogenesis (BrRNA metabolic process,^BncRNA metabolic process,^BmRNA splicing via splicesome^). In order to identify which pathways are over-represented when only PD-specific proteins are considered, an ORA of only-PD_Proteins input list (675 IDs) was performed. To this purpose, we used GO Consortium Biological Process and Reactome as reference databases. Again, we found Bmitophagy^and apoptotic process (Bregulation of apoptosis^), but we also found out Btranslation^and Bmetabolism of amino acid and derivates^ (Table 4) . Strikingly, the latter pathways are overrepresented in the PD_Proteins-Genes analysis, too (Supplementary Table 4 ).
Physical Interaction Network
Starting from the protein input lists previously generated, one for each disease considered (B_Proteins^), we decided to perform a network-based analysis, using the IntAct database as a reference set. With this approach, we generated a direct interactor network (D1 network) for each disease ( Supplementary Fig. 1 ) and we then merged them ( Supplementary Fig. 2 ). In this way, we excluded those nodes that were shared by different diseases and we thus identified Bonly-PD_nodes^. Later, we used this new list of nodes to create new interaction networks (129 nodes). Figure 4a shows the D1 model for the only-PD_nodes. This network highlights the alteration of proteins involved in the regulation of proteolysis (dark green nodes), a process mainly guided by the proteasome complex. Nodes representing proteins that belong to the PD_Proteins-Genes list are highlighted in bold.
Afterwards, NetworkAnalyzer was used to investigate which cellular component complexes are involved in PD. We adjusted the size of nodes according to its degree: the bigger the node, the higher the number of edges (Fig. 4b) . (Fig. 4b) . (Fig. 5) . Alterations in protein level are reported in Supplementary  Table 5 . Figure 5a shows two closely related complexes, the chaperonins CCT complex and the phosphatases PPP2A complex. In the CCT complex, all the chaperonins are down-regulated, with the exception of CCT5 that is down-regulated when SNCA is over-expressed [28] as well as in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated (MPTP-tretated) mice [29] . Conversely, it is up-regulated in mouse neuroblastoma cell lines [30] and in PINK1 knockout mice [31] . With reference to the respiratory chain (Fig. 5b) , the components are altered in different directions, depending on the disease model considered (three yellow nodes: UQCRH, CYC1, and UQCRC1). In addition, results regarding UQCRC2 and UQCRSF1 are ambiguous (Supplementary Table 5 ). In the proteasome complex (Fig. 5c ), we observed a downregulation of subunit 19S ATP-dependent components and the up-regulation of subunit catalytic 20S members.
Discussion
Neurodegenerative diseases are multi-factorial in nature involving several genetic mutations (in coding or regulatory regions) and epigenetic and environmental factors, the greatest risk factor being age [32] . Multi-factorial diseases can be investigated using a global approach at the systems level [33] . Proteomics offers a global snapshot at the molecular level of proteins and consequently processes that regulate neuronal death. The integration of this view with genetic information can help to understand general mechanisms of neurodegeneration. For the purpose of finding molecular pathways specifically involved in PD, we used AD as a control, to eliminate pathway generically linked to neurodegeneration. Moreover, we included ALS in the analysis, being another disorder of motor control, although affecting a distinct neuronal population (i.e., motor neurons). The etiology of AD, PD, and ALS remains largely unknown. Therefore, we performed a meta-analysis of the literature and merged the results of all papers containing proteomics experiments about neuronal modifications in PD, ALS, and AD, including papers on human tissues, animal models, and cellular models, and excluding works about pharmacological effects of particular molecules or peripheral biomarkers.
The meta-analysis approach presented here may have some limits. First, we decided to include only quantitative proteomics studies. We tried to solve this issue using data coming from a genetic database (DisGeNET) and taking into account only the Bconsensus^pathways obtained by the ORA of both protein and gene lists, overcoming at the same time the issue of false results present in the literature. Another weakness of retrieving data from the literature is the few proteomics information about ALS compared to those of PD and AD. Consequently, the molecular picture obtained for ALS was less complete than the one for the other two diseases. Eventually, the ORA of long lists of proteins/genes generates huge lists of pathways where it is difficult to select those biologically relevant. Having access to primary quantitative data should be a method to filter out some less relevant results, using tools such as the gene set enrichment analysis (GSEA). However, the novelty and the strength of this approach is to consider at the same time the results of many studies, derived from different models, thus filtering out experimental bias and highlighting really relevant mechanisms.
There is an extensive evidence that demonstrates the close relationship between ALS and PD at the clinical [34, 35] , genetic [15] , neuroimaging [36] , and pathological level in humans [37, 38] , as well as at the pathological level in preclinical models [39] . In addition, mutations in several ALSrelated genes, e.g., ANG and FUS [40] [41] [42] [43] [44] , could provide a genetic link between ALS and frontotemporal dementia (FTD). Furthermore, C9orf72, TARDBP, and VCP can constitute a common genetic background among ALS and FTD, and, to a lesser extent, PD [42, 45, 46] . The analysis of the three B_Proteins^lists displayed a major overlap between PD and ALS compared to that of AD and ALS. Thus, the two motor disorders may also share common pathways of neurodegeneration even though occurring in different cell types.
In order to identify PD-specific proteins, we eliminated all the proteins shared by AD and ALS and thus generated an only-PD_Proteins input list. Of these proteins, 25 were also found in the DisGeNET database. They probably constitute major molecular hallmarks of PD, since they were never found to be altered in the other two pathologies and were reported both at the proteomic and the genetic levels. Many of them are ribosomal proteins and thus are implicated in protein synthesis. Another category over-represented in this group is the cellular response to stress. Eventually, TALDO1 was identified. Our group has already identified TALDO1 in T-lymphocytes, as part of a protein signature able to discriminate PD patients from control subjects and patients affected by atypical parkinsonism [47] . Therefore, this protein may mirror at the peripheral level an alteration occurring in the CNS [48] . Moreover, since this evidence was only based on one paper in the literature [48] , we verified the up-regulation of the protein in five SN specimens of PD patients, with respect to five control subjects. As a proof-of-principle of our bioinformatics analysis, the increased level of the protein was confirmed in our samples. Although it is difficult to speculate about the link between a single protein and a complex, multifactorial disease, we may envisage a role of the pentose phosphate pathway in the regulation of mitochondrial homeostasis in the presence of enhanced oxidative stress [49] . Indeed, aberrant control of mitochondrial function has been reported in a cellular model that specifically recapitulates dopamine-linked oxidative stress [11] .
Since the strategy of the previous analysis, i.e., the elimination of proteins involved in AD and ALS, could lead to the exclusion of essential pathways, we overcome such an issue by moving from protein identities to the pathway analysis, considering all PD proteins, shared or not by the other two diseases. Therefore, we performed an ORA on the B_Genes" and B_Proteins^input lists, using the GO consortium, to highlight disease-specific processes. We expected that pathways shared by all three diseases were general hallmarks of cell death. Indeed, the ORA underlined the over-representation of the apoptotic process, which we used as a kind of positive control. Moreover, the ORA stressed the involvement of the electron transport chain (ETC) in all three diseases. The respiratory chain, especially in pathological conditions, can be a source of reactive oxygen species (ROS). Markers of oxidative stress and ROS damage are elevated in PD, AD, and ALS. A high level of ROS causes a damage to various cellular components and ultimately results in the activation of apoptosis [3] . Regarding the ALS specific-pathways, the involvement of RNA processing was particularly evident: metabolism (BrRNA metabolic process^, BncRNA metabolic process^), transport (Bnuclear transport^, BNuclear import^, and BRNA transport^), and splicing (BmRNA splicing^) were all overrepresented ontologies. Although mitochondrial membrane organization and mitochondrial transport are involved in AD and PD, notably, Bmitophagy^is over-represented only in PD. Alteration of the mitochondrial quality control and the consequent mitochondrial impairment have been widely associated to apoptosis directly triggered by these organelles (Bapoptotic mitochondrial changes^) [50] . The ORA of the onlyPD_Proteins input list (i.e., proteins involved in PD never related to ALS and AD) again highlighted the importance of mitophagy. This list gave us the opportunity to focus on proteins never associated to AD and ALS. At the same time, important pathways may be neglected due to the exclusion of too many members of the ontology under consideration. Keeping in mind advantages and shortcomings of this sub-list, we decided to perform the ORA using also a database of metabolic pathways, to evidence possible specific mechanisms. Some signal transduction cascades were suggested by the analysis. As an example, the Wnt signaling pathway emerged as a pathway commonly dysregulated in PD [51] .
Eventually, we focused on protein complexes involved specifically in PD. The analysis of the PD interactor network evidenced four protein complexes: the proteasome 26S, the ETC complex III, the CCT complex, and the PPP2A complex. Focusing on these complexes, we decided to retrieve quantitative information from original papers. Since it was impossible to compare papers using different scales and normalization methods, we decided to categorize variations as up-or downregulations. In the proteasome complex, it was possible to identify a different action of the PD pathogenetic process on the expression of members of the catalytic subunit (proteasome 20S) and of the 26S protease regulatory subunit. The former were all up-regulated, whereas the latter were all down-regulated. PD has been considered for long time a proteasome disease [52] and our analysis seems to confirm this hypothesis. In the ETC complex III, proteins were reported to be regulated in different directions by the original papers, probably because of the use of different models [53] . This may indicate different alterations in the respiratory chain due to different perturbations. The involvement of the ETC dysfunction in PD has always been related to complex I [54] , and the inhibition of this complex by MPTP is used to reproduce parkinsonism in animal models [55] . Nevertheless, considering all the results together allowed us to highlight also the role of complex III. The CCT complex has been demonstrated to play an active role in the protection of dopaminergic neurons [56] , being composed by chaperonins. All the proteins of the CCT complex were reported as down-regulated in the papers considered in the present analysis, probably indicating an overwhelming of their re-folding/protective capacities. PPP2A is a protein complex composed by structural (A), regulatory/targeting (B), and catalytic (C) subunits. Some of these subunits are direct interactors of CCT complex chaperonins [57] and are implicated in many PD-related pathways. Indeed, this phosphatase controls Akt phosphorylation and thus macroautophagy [58] , the activity of tyrosine hydroxylase (i.e., dopamine synthesis rate-limiting enzyme) [59] , and alpha-synuclein aggregation [60] .
To sum up, this analysis highlighted processes generically involved in neuronal death and pathways related to the loss of specific neuronal populations in the different diseases. In particular, it clarified cellular pathways specifically involved in PD. Moreover, the analysis highlighted the fundamental role played by four protein complexes in leading neurodegeneration in PD. This may be useful for future research to better understand disease-specific mechanisms and general alterations related to neurodegeneration.
